In recognition of World Hemophilia Day, held on April 17, CSL Behring announced that it is donating ten million international units (IUs) of bleeding disorder protein therapies and contributing a significant financial contribution to the World Federation of Hemophilia (WFH).
CSL Behring said that it has once again committed to donating bleeding disorder protein therapy IUs to the WFH Global Alliance for Progress (GAP) Program and other WFH programs, as well as providing more than $1.1 million in financial support to WFH. Under the agreement, CSL will provide WFH 10 million IUs of one or more of its products from its broad portfolio of bleeding disorder protein therapies over a three-year period, beginning in 2016.
The GAP Program aims to improve the diagnosis and treatment of bleeding disorders in developing countries. In 2009, CSL was the world’s first biotherapies company to make a multiyear commitment to WFH to assist the GAP Program with humanitarian aid coagulation factor donations over an extended period of time. The company will also provide more than $1.1 million in financial support to WFH’s Corporate Partner and GAP programs over the three-year period. Since 2009, CSL has provided nearly 14 million IUs of its bleeding disorder protein therapies to treat people with hemophilia or von Willebrand disease (VWD) in developing countries.
“CSL Behring has long been at the forefront of enabling people with serious conditions to lead normal and health lives,” said Paul Perreault, CEO and Managing Director of CSL Limited. “The GAP Program aligns with CSL Behring’s goal to make meaningful differences in the lives of people who are living with serious diseases, such as hemophilia or von Willebrand disease. We look forward to our continued partnership with WFH as we work together to improve treatment access in developing countries around the world.”
The GAP Program was launched in 2003, with the overarching goals of increasing by 50,000 the worldwide number of people identified/diagnosed with a bleeding disorder, as well as ensuring that 50 percent of those newly-diagnosed are from the world’s most impoverished countries. World Hemophilia Day was established to raise awareness about bleeding disorders and the need to build a family of support for those living with them.
“WFH established the GAP Program to advance our vision of Treatment for All, working to improve diagnosis and access to care for the millions of people who have a rare bleeding disorder yet remain without treatment,” said WFH President Alain Wiell. “CSL Behring shares WFH’s vision in improving diagnosis and treatment access. We are once again grateful for the generous pledge made by CSL Behring as we strive to help fulfill our commitment to introduce clotting factor concentrates in developing countries where people who are living with a bleeding disorder may not be able to access appropriate treatment.”
For more information on World Hemophilia Day, visit: http://www.wfh.org/en/whd.
Source: CSL Behring
Last updated: 4/14/15; 4:45pm EST